Cost-effectiveness of captopril therapy after myocardial infarction

Section for Clinical Epidemiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

OBJECTIVES. This study sought to assess the cost-effectiveness of captopril therapy for survivors of myocardial infarction. BACKGROUND. The recent randomized, controlled Survival and Ventricular Enlargement (SAVE) trial showed that captopril therapy improves survival in survivors of myocardial infarction with an ejection fraction < or = 40%. The present ancillary study was designed to determine how the costs required to achieve this increase in survival compared with those of other medical interventions. METHODS. We developed a decision-analytic model to assess the cost-effectiveness of captopril therapy in 50- to 80-year old survivors of myocardial infarction with an ejection fraction < or = 40%. Data on costs, utilities (health-related quality of life weights) and 4-year survival were obtained directly from the SAVE trial, and long-term survival was estimated using a Markov model. In one set of analyses, we assumed that the survival benefit associated with captopril therapy would persist beyond 4 years (persistent-benefit analyses), whereas in another set we assumed that captopril therapy incurred costs but no survival benefit beyond 4 years (limited-benefit analyses). RESULTS. In the limited-benefit analyses, the incremental cost-effectiveness of captopril therapy ranged from $3,600/quality-adjusted life-year for 80-year old patients to $60,800/quality-adjusted life-year for 50-year old patients. In the persistent-benefit analyses, incremental cost-effectiveness ratios ranged from $3,700 to $10,400/quality-adjusted life-year, depending on age. The outcome was generally not sensitive to changes in estimates of variables when they were varied individually over wide ranges. In a "worst-case" analysis, incremental cost-effectiveness ratios for captopril therapy remained favorable ($8,700 to $29,200/quality-adjusted life-year) for 60- to 80-year old patients but were higher ($217,600/quality-adjusted life-year) for 50-year old patients. CONCLUSIONS. We conclude that the cost-effectiveness of captopril therapy for 50- to 80-year old survivors of myocardial infarction with a low ejection fraction compares favorably with other interventions for survivors of myocardial infarction.

This article has been cited by other articles:

				W. C. Levy, D. Mozaffarian, D. T. Linker, K. W. Kenyon, J. G.F. Cleland, M. Komajda, W. J. Remme, C. Torp-Pedersen, M. Metra, P. A. Poole-Wilson, et al. Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials Eur J Heart Fail, March 1, 2009; 11(3): 256 - 263. [Abstract] [Full Text] [PDF]

				D A Turner, S Paul, M A Stone, A Juarez-Garcia, I Squire, and K Khunti Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care Heart, December 1, 2008; 94(12): 1601 - 1606. [Abstract] [Full Text] [PDF]

				Z. Agha, R. P. Lofgren, and J. V. VanRuiswyk Is Antibiotic Prophylaxis for Bacterial Endocarditis Cost-Effective? Med Decis Making, May 1, 2005; 25(3): 308 - 320. [Abstract] [PDF]

				W. S. Weintraub, Z. Zhang, E. M. Mahoney, P. Kolm, J. A. Spertus, J. Caro, J. Ishak, R. Goldberg, J. Tooley, R. Willke, et al. Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure Circulation, March 8, 2005; 111(9): 1106 - 1113. [Abstract] [Full Text] [PDF]

				J. M. Mrus and J. Tsevat Cost-Effectiveness of Interventions to Reduce Vertical HIV Transmission from Pregnant Women Who Have Not Received Prenatal Care Med Decis Making, January 1, 2004; 24(1): 30 - 39. [Abstract] [PDF]

				J. M. Neuner, M. B. Hamel, R. S. Phillips, K. Bona, and M. D. Aronson Diagnosis and Management of Adults with Pharyngitis: A Cost-Effectiveness Analysis Ann Intern Med, July 15, 2003; 139(2): 113 - 122. [Abstract] [Full Text] [PDF]

				T. R. Gildea, K. M. Shermock, M. E. Singer, and J. K. Stoller Cost-Effectiveness Analysis of Augmentation Therapy for Severe {alpha}1-Antitrypsin Deficiency Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1387 - 1392. [Abstract] [Full Text] [PDF]

				T A McDonagh Screening for left ventricular dysfunction: a step too far? Heart, October 1, 2002; 88(90002): ii12 - 14. [Full Text] [PDF]

				W. M. Hart, C. Rubio-Terres, F. Pajuelo, and J. R. G. Juanatey Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study Eur J Heart Fail, August 1, 2002; 4(4): 553 - 558. [Abstract] [Full Text] [PDF]

				B. Riegel, B. Carlson, Z. Kopp, B. LePetri, D. Glaser, and A. Unger Effect of a Standardized Nurse Case-Management Telephone Intervention on Resource Use in Patients With Chronic Heart Failure Arch Intern Med, March 25, 2002; 162(6): 705 - 712. [Abstract] [Full Text] [PDF]

				D. C. ANGUS, A. A. MUSTHAFA, G. CLERMONT, M. F. GRIFFIN, W. T. LINDE-ZWIRBLE, T. T. DREMSIZOV, and M. R. PINSKY Quality-adjusted Survival in the First Year after the Acute Respiratory Distress Syndrome Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1389 - 1394. [Abstract] [Full Text] [PDF]

				K. A. Phillips, M. G. Shlipak, P. Coxson, P. A. Heidenreich, M. G. M. Hunink, P. A. Goldman, L. W. Williams, M. C. Weinstein, and L. Goldman Health and Economic Benefits of Increased {beta}-Blocker Use Following Myocardial Infarction JAMA, December 6, 2000; 284(21): 2748 - 2754. [Abstract] [Full Text] [PDF]

				M. W. Rich and R. F. Nease Cost-effectiveness Analysis in Clinical Practice: The Case of Heart Failure Arch Intern Med, August 9, 1999; 159(15): 1690 - 1700. [Abstract] [Full Text] [PDF]

				J. Tsevat and U. R. Kotagal Management of Sore Throats in Children: A Cost-effectiveness Analysis Arch Pediatr Adolesc Med, July 1, 1999; 153(7): 681 - 688. [Abstract] [Full Text] [PDF]

				The Large State Peer Review Organization Consortiu Heart Failure Treatment With Angiotensin-Converting Enzyme Inhibitors in Hospitalized Medicare Patients in 10 Large States Arch Intern Med, May 26, 1997; 157(10): 1103 - 1108. [Abstract] [PDF]

				K. M. Kuntz, J. Tsevat, L. Goldman, and M. C. Weinstein Cost-effectiveness of Routine Coronary Angiography After Acute Myocardial Infarction Circulation, September 1, 1996; 94(5): 957 - 965. [Abstract] [Full Text]

				S. C. Smith Jr Risk-Reduction Therapy: The Challenge to Change : Presented at the 68th Scientific Sessions of the American Heart Association November 13, 1995 Anaheim, California Circulation, June 15, 1996; 93(12): 2205 - 2211. [Full Text]